



## **JP Morgan Annual Healthcare Conference to Webcast Alkermes' Corporate Presentation**

January 5, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2005--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by JP Morgan on Wednesday, January 12, 2005 at 11:30 a.m. EST (8:30 a.m. PST). Richard Pops, CEO of Alkermes, will provide an overview of the company and review the company's corporate goals for 2005. The presentation will be webcast from the Westin St. Francis Hotel in San Francisco, California, and may be accessed under the investor relation's tab at [www.alkermes.com](http://www.alkermes.com). The presentation will be archived for 30 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, Risperdal(R) Consta(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag, a division of Johnson & Johnson. The Company's lead proprietary product candidate, Vivitrex(R) ((naltrexone) long-acting injection), is a once-a-month injection for the treatment of alcohol dependence. Alkermes has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technology and expertise. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.  
Rebecca Peterson  
Director, Corporate Communications  
(617) 583-6378  
or  
Jaren Madden  
Manager, Corporate Communications  
(617) 583-6402

SOURCE: Alkermes, Inc.